Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer

Abstract

BACKGROUND: Activating mutations in AKT1 and PIK3CA are undercharacterised in metastatic castration-resistant prostate cancer (mCRPC), but are linked to activation of phosphatidylinositol 3-kinase (PI3K) signalling and sensitivity to pathway inhibitors in other cancers. OBJECTIVE: To determine the prevalence, genomic context, and clinical associations of AKT1/PIK3CA activating mutations in mCRPC.

Authors

Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A

Journal

European Urology, Vol. 78, No. 6, pp. 834–844

Publisher

Elsevier

Publication Date

December 2020

DOI

10.1016/j.eururo.2020.04.058

ISSN

0302-2838

Associated Experts

Sebastien Hotte

Professor, Faculty of Health Sciences

Visit profile

Labels